Based on medical history, nine patients (3 ovarian, 6 breast cancer) had pathogenic BRCA mutation (3 germline (g)BRCA1, 1 somatic (s)BRCA1, 5 gBRCA2), while 15 patients (6 ovarian, 5 breast, 2 uterine, 1 endometrial, 1 prostate cancer) had wild‐type BRCA and 3 patients (2 ovarian, 1 breast) had wild‐type HRD. Here, BRCA1 is linked to prostate carcinoma.